A new equine parasite supplement to the online peer-reviewed publication Parasites and Vectors has been published by Fort Dodge.
Entitled "Equine parasites: diagnosis and control - a current perspective," it contains papers on a range of topics including a major European resistance study into key anthelmintic molecules. It is authored by equine parasitology experts and opinion leaders from around the world and was first published in September 2009. It is freely available at http://www.parasitesandvectors.com/
Fort Dodge has released figures today which point to a continued modest slowdown in the UK veterinary sector, being mitigated by a slight increase in average transaction value (the amount a client spends in a year).
Matthew Rowe, Companion Animal Marketing Manager at Fort Dodge, said: "It's been clear for some time that the veterinary sector is being hit by static growth and an increasingly competitive environment. The reduction in turnover being experienced by many practices is primarily down to current clients visiting less often and fewer new clients being attracted."
Key findings of the Fort Dodge Index for the first quarter of 2009 are:
Alan Robinson said: "In the current climate, the only contributor to turnover growth in many practices seems to be a steady rise in the price of professional fees, consultations and surgery. These have continued to push up average transaction values (by 1.4%) and client values (1.2%) in this first quarter of 2009 despite reducing visit frequency. Drug related income increases seem to be driven by a small increase of POM mark-ups in many practices.
"But this alone will not sustain a successful business and, with transaction volumes still falling, the priority for practices is to maintain client footfall despite increasing competition and falling pet ownership. In today's market, retaining clients is a cheaper and more effective way to maintain client and patient numbers so an emphasis on 'bonding' clients though preventative health care and heath maintenance programmes is key.
"We're seeing a steady increase in the number of practices running these programmes but the percentage of pets involved is still woefully low so the message is that practices can and must do better.
Fort Dodge has announced that a challenge study has demonstrated the ability of Duvaxyn® IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Sydney/07 (H3N8) two weeks after a two dose primary course. This strain was responsible for the financially devastating equine influenza outbreak in Australia in August 2007.
Duvaxyn IE-T Plus is an inactivated whole virus equine influenza vaccine, adjuvanted with an aqueous-based adjuvant. According to Fort Dodge, experts at a recent WHO meeting on human vaccines expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins in the vaccine*.
The study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two dose of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Sydney/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
Helen Barnes, EMEA Equine Business Manager for Fort Dodge, said: "The results of this challenge study provide reassurance for owners that horses vaccinated with Duvaxyn will be protected against circulating strains of equine influenza, including the Sydney strain which proved so damaging.
"As the benefits offered by whole virus technology are increasingly recognised, the popularity of vaccines based on this technology is re-emerging, particularly to combat a potential pandemic.
"The entire Duvaxyn range of equine vaccines, including the recently licensed Duvaxyn WNV for West Nile Virus, are based on the whole virus approach as we believe it offers a broad and consistent level of protection."
Fort Dodge, which supplies Bluetongue vaccine in continental Europe, has licensed its cattle vaccine in the UK and is now launching the product onto the UK market.
The company has already won and met tenders from several European governments, including France, Spain, Italy, Portugal Germany, Switzerland, Belgium and the Czech Republic for its Zulvac 8® Bovis vaccine and says it is the only international company to have produced vaccines for the most commonly occurring serotypes of the disease including 8, 4 and 1.
Approved by the VMD with a Provisional Marketing Authorisation, Zulvac 8 is available in 50 dose and 10 dose packs. The key claims are active immunisation against Bluetongue serotype 8 of cattle from 2.5 months old and a significant reduction of viraemia.
The vaccine is administered in 2 x 2 ml doses at three week intervals given by intra muscular injection and the product is supported by a fixed 2ml multidose applicator with Sterimatic needle protector and cleaning system to ensure accurate dosing and hygienic conditions.
John Hanley, Managing Director of Fort Dodge UK, said: "We were first to market with our Zulvac 8 product in three European countries and have received an Award for Agricultural Merit from the Spanish Government for our work in Bluetongue control. Following the licensing of Zulvac 8 Bovis in the UK we now have the opportunity to launch the product onto the UK market.
"In terms of pricing, Zulvac 8 is competitive per dose against other products in the market and it is supported by the experience gained in Europe with millions of animals already vaccinated. We're delighted that the VMD have authorised the vaccine and believe its availability can play a key role in protecting the UK's cattle from this dreadful disease."
The product is authorised for use by cattle farmers in the protection zone only, and will require veterinary prescription. Farmers can administer the vaccine to their cattle and the 2ml intra-muscular injection will be an advantage in aiding administration especially when used with Zulvac Bovis applicator with sterimatic needle protector and cleaning system.
The first batches will be available from veterinary wholesalers from week commencing 22nd September 2008.
Fort Dodge has unveiled an initiative to help practices improve peri-operative care and the management of hospitalised cases with the launch of its Early Warning Scoring System (EWSS) kit.
The kit contains cat and dog anaesthesia and observation charts for the effective monitoring of cats and dogs during operations, post-operatively and for hospitalised medical cases.
EWSS observation charts are widely used in the NHS but this is believed to be the first time that such a system has been developed specifically for use in veterinary practices.
They have been designed by Mike Davies BVetMed CertVR CertSAO FRCVS, Technical Services Manager at Fort Dodge, and are intended to help veterinary nurses and veterinary surgeons identify patients whose condition is deteriorating before they reach a critical state.
Mike Davies speaks around the country on preventive medicine and geriatrics and his experience of working closely with practices is that many do not have good protocols in place for nurse monitoring of patients. The EWSS grades parameters such as heart rate, respiratory rate, blood pressure and CNS response and the charts incorporate areas in which the practice can record pain using a visual analogue scale or a numeric scoring system.
The company has also launched Dorbene vet, a new product providing fast-acting sedation and analgesia for dogs and cats. Its active ingredient is the trusted and well proven alpha-2 agonist medetomidine hydrochloride, which affects the nervous system by inhibiting noradrenaline mediated neurotransmission. A dosing guide for Dorbene vet is also included in the EWSS.
The launch of Dorbene vet complements Fort Dodge's existing companion animal products, analgesic Torbugesic and dissociative anaesthetic Ketaset. Used alone it offers dose-related sedation within 10-15 minutes, which is rapidly reversible using the alpha-2 antagonist atipamezole for predictable recovery. It is presented in 10 ml and 50 ml multi dose vials in amber coloured glass which protects the product from light.
For further information on the EWSS or Dorbene vet, contact Fort Dodge on 01489 781711.
Fort Dodge (makers of Equest equine worming brands, and Deosect), is launching a new Equine Parasites Reference Manual.
The manual, which is supported by AHDA, AMTRA and BEVA, is billed as 'an objective and comprehensive reference guide covering endoparasites and ectoparasites and their control, as well as offering prescribing tips, a glossary of terms and reference sources'.
Fort Dodge has produced the manual to provide an ‘all in one’ guide to support veterinary professionals and Suitably Qualified People (SQPs) involved in prescribing equine parasite treatments. It brings together, in an A5 spiral bound booklet, all the information they may need on the full range of licensed veterinary medicines to control equine parasites of concern in the UK. It will be launched at BETA (17-19 February at the NEC).
For further information about the manual (or to get a copy), please contact Fort Dodge on 01489 781711.